Skip to main content
Toggle navigation
Search
Home
Back
Favorite
0
Like
Facebook
Print
Session XXII: Colorectal Cancer: Metastatic Disease
O-6: Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients: results of the phase III randomized TRIPLETE study by GONO
Saturday, July 2, 2022
09:30 – 09:42
Location: Auditorium A; Level 0
Abstract Presenter(s)
DR
Daniele Rossini
